Xsensio, a Lausanne-based DeepTech company developing near real-time continuous biochemical monitoring, announced the successful closing of a €6 million ($7 million) oversubscribed Series A financing round.
The round was led by VC firm WI Harper, with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.
“This Series A marks a pivotal step in translating continuous biochemical monitoring into real clinical environments,” declares Esmeralda Megally, CEO of Xsensio. “For the first time, clinicians can access key continuous biochemical data in real time, information that has historically been unavailable at the point of care. This capability has the potential to fundamentally improve how patients are monitored and treated.”
Xsensio operates within a European wearable and continuous biosensing segment that has seen sustained funding momentum throughout 2025 and early 2026.
In July 2025, London-based Sava Technologies secured €16.6 million in a Series A round to advance its wearable molecular health monitoring microsensor technology and progress towards regulatory approval and commercialisation. Earlier in February 2025, London-based Level Zero Health raised €6.6 million in pre-Seed funding to develop what it describes as the world’s first continuous hormone monitoring wearable. In Switzerland, Liom closed a €13.9 million round in December 2025 to further its non-invasive continuous glucose monitoring technology. Meanwhile, Zurich-based Ahead Health raised €5.1 million in January 2026 to expand its preventive healthcare testing and analytics platform.
Collectively, these disclosed rounds amount to over €42 million invested into European startups developing continuous or wearable health monitoring solutions during 2025 and early 2026, providing sector context for Xsensio’s €6 million Series A and indicating continued capital allocation towards real-time, data-driven healthcare monitoring technologies.
“Our collaboration with Texas Instruments significantly strengthens our path to advanced, scalable semiconductor technology,” adds Adrian Ionescu, CTO of Xsensio. “By combining our biosensing innovation with world-class semiconductor expertise, we are building a platform designed not only for clinical impact, but also for reliable, cost-effective deployment.”
Founded in 2014, Xsensio is developing the Lab-on-Skin wearable biosensing platform to deliver continuous, real-time biochemical information for personalised and preventive healthcare.
Developed at the Nanolab of the Swiss Federal Institute of Technology, this first product focutilizes on early detection of organ dysfunction, addressing high-impact challenges in critical care, oncology, and post-surgical recovery. The sensing chip analyses biomarkers in the interstitial fluid (ISF) – the body’s natural window into inflammation, metabolism, and organ function.
The chip integrates multiple sensors tarobtaining a range of biomarkers – from metabolites and ions to proteins and hormones. Its modular and customisable architecture enables them to adapt the same platform across diverse clinical utilize cases. All data is created securely available in real time to patients, caregivers, or healthcare providers, enabling earlier interventions and more personalised care.
Xsensio is developing a scalable and proprietary platform of wearable products and services, all built on their core Lab-on-Skin system. Each solution combines:
-
Their customised multi-sensor chip
-
A proprietary skin interface
-
Wireless communication for on-demand or continuous data streaming
“We believe Xsensio is defining a new category in wearable biosensing. Given the company’s strong progress and market potential, we are excited to be leading this investment round,” shares Wilson Wu, Partner at WI Harper.
Along with the funding, Xsensio announced a long-term collaboration with Texas Instruments, a global leader in semiconductor technology. This collaboration brings unique expertise in CMOS integration, miniaturisation, and large-scale manufacturability of biosensing systems, further strengthening Xsensio’s industrial scalability.
Leave a Reply